The Asia Pacific Metabolomics Market Size is valued at USD 400 Million in 2020 and estimated to grow at a CAGR of 17.92%, to reach USD 900 Million by 2024 during the forecast period 2019-2024.
Metabolomics is the rational study of concoction forms comprising metabolites. In particular, metabolomics is the "deliberate investigation of the one of a kind synthetic fingerprints that particular cell forms desert", the study of their little molecules metabolite profiles. The metabolome signifies to the accumulation of all metabolites in natural fleshy tissue, cell, organ or life form, which are the final consequences of cell processes. The Asia Pacific Metabolomics market is developing at a very quick speed.
The increasing biotech ground-breaking work and pharmaceutical consumption are prompting persistent headways in innovation, spelling development for the worldwide metabolomics market. The developing acceptance of metabolomics in customized medicines is one of the key variables boosting the growth of the market. Then again, there are issues with respect to information handling and information examination, which can represent a test for the market. The high cost of instruments and devices can equally be an issue. Further, the necessity for very much skilled specialists and the absence of the same is limiting the improvement of the metabolomics market.
This research report on the Asia-Pacific Metabolomics Market has been segmented and sub-segmented into the following categories:
By Product:
By Indication:
By Application:
By Country:
On the basis of application, the Biomarker Discovery segment had the largest share in 2016 in the global metabolomics market. Efficiency and reliability have been cited as the reason for the growth of biomarkers. However, collaboration between biotechnology and pharmaceutical companies, the personalized medical segment is expected to have the highest CAGR.
On the basis of region, China and India are likely to increase the market because of the huge population. Also, Asia Pacific is the largest growing segment.
Noteworthy companies leading the Asia Pacific Metabolomics Market analyzed in this report are Agilent Technologies, Inc. (U.S.), Human Metabolome Technologies, Inc. (Japan), Thermo Fisher Scientific, Inc. (U.S.), LECO Corporation (U.S.), Bruker Corporation (U.S.), Shimadzu Corporation (Japan), Metabolon Inc. (U.S.), Danaher Corporation (U.S.), Biocrates Life Sciences AG (Austria), and Waters Corporation (U.S.).
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Metabolomic Instruments
5.1.1.1Separation Techniques
5.1.1.1.1 Gas Chromatography (GC)
5.1.1.1.2 Capillary Electrophoresis (CE)
5.1.1.1.3 High-performance Liquid Chromatography (HPLC)
5.1.1.1.4 Ultra-performance Liquid Chromatography (UPLC)
5.1.1.2 Detection Tools
5.1.1.2.1 Mass Spectrometry
5.1.1.2.2 Nuclear Magnetic Resonance Spectroscopy
5.1.1.2.3 Surface-Based Mass Analysis
5.1.2 Metabolomics Bioinformatics Tools and Services
5.1.2.1 Bioinformatics Tools & Databases
5.1.2.2 Bioinformatics Services
5.1.3 Y-o-Y Growth Analysis, By Product
5.1.4 Market Attractiveness Analysis, By Product
5.1.5 Market Share Analysis, By Product
5.2 Indication
5.2.1 Cancer
5.2.2 Cardiovascular Disorders
5.2.3 Inborn errors
5.2.4 Neurological Errors
5.2.5 Other Indications
5.2.4 Y-o-Y Growth Analysis, By Indication
5.2.5 Market Attractiveness Analysis, By Indication
5.2.6 Market Share Analysis, By Indication
5.3 Application
5.3.1 Nutrigenomics
5.3.2 Toxicology
5.3.3 Biomarker & Drug Discovery
5.3.4 Functional Genomics
5.3.5 Personalized Medicine
5.3.6 Other Applications
5.3.7 Y-o-Y Growth Analysis, By Application
5.3.8 Market Attractiveness Analysis, By Application
5.3.9 Market Share Analysis, By Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Indication
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Indication
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Indication
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Waters Corporation (U.S.)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Agilent Technologies, Inc. (U.S.)
8.3 Human Metabolome Technologies, Inc. (Japan)
8.4 Thermo Fisher Scientific, Inc. (U.S.)
8.5 LECO Corporation (U.S.)
8.6 Bruker Corporation (U.S.)
8.7 Shimadzu Corporation (Japan)
8.8 Metabolon Inc. (U.S.)
8.9 Danaher Corporation (U.S.)
8.10 Biocrates Life Sciences AG (Austria)
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
